We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Novel Microfilarial Antigen Diagnoses Lymphatic Filariasis Infections

By LabMedica International staff writers
Posted on 08 Jun 2022
Print article
Image: Immunolocalization of BmR1 homologues showing immunohistochemical results from worm sections that were processed (Photo courtesy of Washington University School of Medicine)
Image: Immunolocalization of BmR1 homologues showing immunohistochemical results from worm sections that were processed (Photo courtesy of Washington University School of Medicine)

Lymphatic filariasis is a neglected tropical disease caused by the filarial nematodes Wuchereria bancrofti, Brugia malayi and Brugia timori. Lymphatic filariasis (LF) is a deforming and disabling disease caused by parasitic nematodes that are transmitted by mosquitoes.

Antibodies to some filarial antigens become detectable in blood sooner after exposure or infection, than microfilaria (Mf) or circulating filarial antigen (CFA). Furthermore, antibody assays may be more sensitive than tests for CFA or Mf for detecting filarial infections or exposure to infection in children.

Infectious Disease Specialists at the Washington University School of Medicine (St Louis, MO, USA) report the discovery and characterization of a novel W. bancrofti antigen, Wb-Bhp-1, which is a homologue of the Brugia malayi protein used in antibody tests to monitor filariasis elimination in areas of Asia where LF is caused by Brugia species. The team used various techniques to study the antigen diagnostic potential, including cloning and expression, tissue fixation and immunohistochemistry, immunoblot analysis, and indirect ELISA. They tested sera or plasma from patients infected with W. bancrofti, B. malayi, Onchocerca volvulus and Loa loa. Slides were examined on an Olympus -BX40 microscope and photographed on an Olympus DP70 microscope digital camera (Olympus, Tokyo Japan).

The scientists reported that immunohistology showed that anti-Wb-Bhp-1 antibodies primarily bind to Mf. Plasma from 124 of 224 (55%) microfilaremic individuals had IgG4 antibodies to Wb-Bhp-1 by ELISA. Serologic reactivity to Wb-Bhp-1 varied widely with samples from different regions (sensitivity range 32%–92%), with 77% sensitivity for 116 samples collected from microfilaremic individuals outside of sub-Saharan Africa. The team screened sera from people infected with W. bancrofti, and 12 of 13 (92%) reacted with Wb-Bhp-1 by immunoblot. The scientists tested 224 sera from individuals with W. bancrofti microfilaremia collected in Sri Lanka, India, Papua New Guinea, Egypt and Côte d’Ivoire. They found that 124/ 224 (55%) sera had anti-Wb-Bhp-1 IgG4 ELISA titers above the threshold of 0.2 OD490, using a BioTek ELx808 plate reader (Agilent Technologies, Santa Clara, CA, USA).

The authors concluded that Wb-Bhp-1, a W. bancrofti homologue of BmR1, is a promising microfilarial antigen for diagnosis of bancroftian filariasis. Specificity testing showed that the Wb-Bhp-1 ELISA had low-level cross-reactivity with samples from people with onchocerciasis or loiasis. Wb-Bhp-1 serology may be especially useful in countries where the combination of ivermectin, diethylcarbamazine (DEC) and albendazole (IDA) can be used to accelerate LF elimination. The study was published on May 23, 2022 in the journal PLOS Neglected Tropical Diseases.

Related Links:
Washington University School of Medicine 
Olympus 
Agilent Technologies

Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Mycoplasma Pneumoniae Virus Test
Mycoplasma Pneumoniae Virus Detection Kit
New
H.pylori Test
Humasis H.pylori Card

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.